Multimodality imaging in restrictive cardiomyopathies: an EACVI expert consensus document: In collaboration with the 'Working Group on myocardial and pericardial diseases' of the European Society of Cardiology Endorsed by the Indian Academy of Echocardiography
[en] Restrictive cardiomyopathies (RCMs) are a diverse group of myocardial diseases with a wide range of aetiologies, including familial, genetic and acquired diseases and ranging from very rare to relatively frequent cardiac disorders. In all these diseases, imaging techniques play a central role. Advanced imaging techniques provide important novel data on the diagnostic and prognostic assessment of RCMs. This EACVI consensus document provides comprehensive information for the appropriateness of all non-invasive imaging techniques for the diagnosis, prognostic evaluation, and management of patients with RCM.
Disciplines :
Cardiovascular & respiratory systems
Author, co-author :
Habib, G
Bucciarelli-Ducci, C
Caforio, ALP
Cardim, Nuno
Charron, P
Cosyns, Bernard
Dehaene, A
Derumeaux, G
Donal, Erwan
Dweck, MR
Edvardsen, Thor
Erba, Paola Anna
Ernande, L
Gaemperli, O
Galderisi, Maurizio
Grapsa, J
Jacquier, A
Klingel, K
Lancellotti, Patrizio ; Université de Liège > Département des sciences cliniques > Imagerie cardiaque fonctionnelle par échographie
Multimodality imaging in restrictive cardiomyopathies: an EACVI expert consensus document: In collaboration with the 'Working Group on myocardial and pericardial diseases' of the European Society of Cardiology Endorsed by the Indian Academy of Echocardiography
Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P et al. Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2008;29:270-6.
Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, O'Connell J et al. Report of the 1995 World Health Organization/International Society and federation of cardiology task force on the definition and classification of cardiomyopathies. Circulation 1996;93:841-2.
Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 2006;113:1807-16.
Nihoyannopoulos P, Dawson D. Restritive cardiomyopathies. Eur J Echocardiogr 2009;10:23-33.
Kushwaha SS, Fallon JT, Fuster V. Restrictive cardiomyopathy. N Engl J Med 1997;336:267-76.
Tam JW, Shaikh N, Sutherland E. Echocardiographic assessment of patients with hypertrophic and restrictive cardiomyopathy: imaging and echocardiography. Curr Opin Cardiol 2002;17:470-7.
Hancock EW. Differential diagnosis of restrictive cardiomyopathy and constrictive pericarditis. Heart 2001;86:343-9.
Nagueh SF, Smiseth OA, Appleton CP, Byrd BF 3rd, Dokainish H, Edvardsen T et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2016;17:1321-60.
Klein AL, Hatle LK, Taliercio CP, Oh JK, Kyle RA, Gertz MA et al. Prognostic significance of Doppler measures of diastolic function in cardiac amyloidosis. A Doppler echocardiography study. Circulation 1991;83:808-816.
Hyodo E, Hozumi T, Takemoto Y, Watanabe H, Muro T, Yamagishi H et al. Early detection of cardiac involvement in patients with sarcoidosis by a noninvasive method with ultrasonic tissue characterisation. Heart 2004;90:1275-80.
Bhandari AK, Nanda NC. Myocardial texture characterization by twodimensional echocardiography. Am J Cardiol 1983;51:817
Schiano-Lomoriello V, Galderisi M, Mele D, Esposito R, Cerciello G, Buonauro A et al. Longitudinal strain of left ventricular basal segments and E/e' ratio differentiate primary cardiac amyloidosis at presentation from hypertensive hypertrophy: an automated function imaging study. Echocardiography 2016; doi: 10.1111/echo.13278.
Sengupta PP, Krishnamoorthy VK, Abhayaratna WP, Korinek J, Belohlavek M, Sundt TM 3rd et al. Disparate patterns of left ventricular mechanics differentiate constrictive pericarditis from restrictive cardiomyopathy. JACC Cardiovasc Imaging 2008;1:29-38.
Kramer CM, Barkhausen J, Flamm SD, Kim RJ, Nagel E. Society for Cardiovascular Magnetic Resonance Board of Trustees Task Force on Standardized Protocols. Standardized cardiovascular magnetic resonance (CMR) protocols 2013 update. J Cardiovasc Magn Reson 2013;15:91.
Bellenger NG, Davies LC, Francis JM, Coats AJ, Pennell DJ. Reduction in sample size for studies of remodeling in heart failure by the use of cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2000;2:271-8.
Cosyns B, Plein S, Nihoyanopoulos P, Smiseth O, Achenbach S, Andrade MJ et al; European Association of Cardiovascular Imaging (EACVI); European Society of Cardiology Working Group (ESC WG) on Myocardial and Pericardial diseases. European Association of Cardiovascular Imaging (EACVI) position paper: multimodality imaging in pericardial disease. Eur Heart J Cardiovasc Imaging 2015;16:12-31.
Francone M, Dymarkowski S, Kalantzi M, Rademakers FE, Bogaert J. Assessment of ventricular coupling with real-time cine MRI and its value to differentiate constrictive pericarditis from restrictive cardiomyopathy. Eur Radiol 2006;16:944-51.
Sado DM, White SK, Piechnik SK, Banypersad SM, Treibel T, Captur G et al. Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping. Circ Cardiovasc Imaging 2013;6:392-8.
Fontana M, Pica S, Reant P, Abdel-Gadir A, Treibel TA, Banypersad SM et al. Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 2015;132:1570-9.
Schelbert EB, Piehler KM, Zareba KM, Moon JC, Ugander M, Messroghli DR et al. Myocardial fibrosis quantified by extracellular volume is associated with subsequent hospitalization for heart failure, death, or both across the spectrum of ejection fraction and heart failure stage. J Am Heart Assoc 2015;4:12.
Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH et al. Cardiovascular T2-star (T2∗) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001;22:2171-9.
Modell B, Khan M, Darlison M, Westwood MA, Ingram D, Pennell DJ. Improved survival of thalassaemia major in the UK and relation to T2∗ cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2008;10:42.
Karamitsos TD, Piechnik SK, Banypersad SM, Fontana M, Ntusi NB, Ferreira VM et al. Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging 2013;6:488-97.
Banypersad SM, Sado DM, Flett AS, Gibbs SD, Pinney JH, Maestrini V et al. Quantification of myocardial extracellular volume fraction in systemic AL amyloidosis: an equilibrium contrast cardiovascular magnetic resonance study. Circ Cardiovasc Imaging 2013;6:34-9.
Alam MH, Auger D, McGill LA, Smith GC, He T, Izgi C et al. Comparison of 3 T and 1.5 T for T2∗ magnetic resonance of tissue iron. J Cardiovasc Magn Reson 2016;18:40.
Yared K, Baggish AL, Picard MH, Hoffmann U, Hung J. Multimodality imaging of pericardial diseases. JACC Cardiovascular imaging 2010;3:650-60.
Zhao L, Ma X, Feuchtner GM, Zhang C, Fan Z. Quantification of myocardial delayed enhancement and wall thickness in hypertrophic cardiomyopathy: multidetector computed tomography versus magnetic resonance imaging. European journal of radiology 2014;83:1778-85.
Hamilton-Craig C, Seltmann M, Ropers D, Achenbach S. Myocardial viability by dual-energy delayed enhancement computed tomography. JACC Cardiovascular imaging 2011;4:207-8.
Bandula S, Banypersad SM, Sado D, Flett AS, Punwani S, Taylor SA et al. Measurement of tissue interstitial volume in healthy patients and those with amyloidosis with equilibrium contrast-enhanced mr imaging. Radiology 2013;268:858-64.
Kula RW, Engel WK, Line BR. Scanning for soft-tissue amyloid. Lancet 1977;1:92-3.
Aljaroudi WA, Desai MY, Tang WH, Phelan D, Cerqueira MD, Jaber WA. Role of imaging in the diagnosis and management of patients with cardiac amyloidosis: state of the art review and focus on emerging nuclear techniques. J Nucl Cardiol 2014;21:271-83.
Glaudemans AW, van Rheenen RW, van den Berg MP, Noordzij W, Koole M, Blokzijl H et al. Bone scintigraphy with (99m)technetium-hydroxymethylene diphosphonate allows early diagnosis of cardiac involvement in patients with transthyretin-derived systemic amyloidosis. Amyloid 2014;21:35-44.
Minutoli F, Di Bella G, Mazzeo A, Donato R, Russo M, Scribano E et al. Comparison between (99m)Tc-diphosphonate imaging and MRI with late gadolinium enhancement in evaluating cardiac involvement in patients with transthyretin familial amyloid polyneuropathy. AJR Am J Roentgenol 2013;200:W256-65.
Coutinho MC, Cortez-Dias N, Cantinho G, Conceição I, Oliveira A, Bordalo e Sá A et al. Reduced myocardial 123-iodine metaiodobenzylguanidine uptake: a prognostic marker in familial amyloid polyneuropathy. Circ Cardiovasc Imaging 2013;6:627-36.
Youssef G, Beanlands RSB, Birnie DH, Nery PB. Cardiac sarcoidosis: applications of imaging in diagnosis and directing treatment. Heart 2011;97:2078-87.
Ohira H, Tsujino I, Ishimaru S, Oyama N, Takei T, Tsukamoto E et al. Myocardial imaging with 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis. Eur J Nucl Med Mol Imaging 2008;35:933-41.
Apgral R, Dweck MR, Trivieri MG, Robson PM, Karakatsanis N, Mani V et al. Clinical Utility of Combined FDG-PET/MR to Assess Myocardial Disease. JACC Cardiovasc Imaging 2016 Jun 29; pii:S1936-878X(16)30259-5. doi: 10.1016/j.jcmg.2016.02.029 [Epub ahead of print].
Mogensen J, Arbustini E. Restrictive cardiomyopathy. Curr Opin Cardiol 2009;24:214-20.
Arbustini E, Morbini P, Grasso M, Fasani R, Verga L, Bellini O et al. Restrictive cardiomyopathy, atrioventricular block and mild to subclinical myopathy in patients with desmin-immunoreactive material deposits. J Am Coll Cardiol 1998;31:645-53.
Arbustini E, Buonanno C, Trevi G, Pennelli N, Ferrans VJ, Thiene G. Cardiac ultrastructure in primary restrictive cardiomyopathy. Chest 1983;84:236-8.
Cannavale A, Ordovas KG, Rame EJ, Higgins CB. Hypertrophic cardiomyopathy with restrictive phenotype and myocardial crypts. J Thorac Imaging 2010;25:W121-3.
Rapezzi C, Lorenzini M, Longhi S, Milandri A, Gagliardi C, Bartolomei I et al. Cardiac amyloidosis: the great pretender. Heart Fail Rev 2015;20:117-24.
Rapezzi C, Arbustini E, Caforio AL et al. Diagnostic work-up in cardiomyopathies: bridging the gap between clinical phenotypes and final diagnosis. A position statement from the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2013;34:1448-58.
Koyama J, Ikeda S, Ikeda U. Echocardiographic assessment of the cardiac amyloidoses. Circ J 2015;79:721-34.
Feng D, Edwards WD, Oh JK, Chandrasekaran K, Grogan M, Martinez MW et al. Intracardiac thrombosis and embolism in patients with cardiac amyloidosis. Circulation 2007;116:2420-6.
Innelli P, Galderisi M, Catalano L, Martorelli MC, Olibet M, Pardo M et al. Detection of increased left ventricular filling pressure by pulsed tissue Doppler in cardiac amyloidosis. J Cardiovasc Med 2006;7:742-7.
Tendler A, Helmke S, Teruya S, Alvarez J, Maurer MS. The myocardial contraction fraction is superior to ejection fraction in predicting survival in patients with AL cardiac amyloidosis. Amyloid 2015;22:61-6.
Phelan D, Collier P, Thavendiranathan P, Popović ZB, Hanna M, Plana JC et al. Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart 2012;98:1442-8.
Schiano-Lomoriello V, Galderisi M, Mele D, Esposito R, Cerciello G, Buonauro A et al. Longitudinal strain of left ventricular basal segments and E/e' ratio differentiate primary cardiac amyloidosis at presentation from hypertensive hypertrophy: an automated function imaging study. Echocardiography 2016;33:1335-43.
Bellavia D, Pellikka PA, Al-Zahrani GB, Abraham TP, Dispenzieri A, Miyazaki C et al. Independent predictors of survival in primary systemic (Al) amyloidosis, including cardiac biomarkers and left ventricular strain imaging: an observational cohort study. J Am Soc Echocardiogr 2010;23:643-52.
Ternacle J, Bodez D, Guellich A, Audureau E, Rappeneau S, Lim P et al. Causes and consequences of longitudinal LV dysfunction assessed by 2D strain echocardiography in cardiac amyloidosis. JACC Cardiovasc Imaging 2016;9:126-38.
Quarta CC, Solomon SD, Uraizee I, Kruger J, Longhi S, Ferlito M et al. Left Ventricular structure and function in TTR-related versus AL cardiac amyloidosis. Circulation 2014;129:1840-9.
Maceira AM, Joshi J, Prasad SK, Moon JC, Perugini E, Harding I et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 2005;111:186-93.
Vogelsberg H, Mahrholdt H, Deluigi CC, Yilmaz A, Kispert EM, Greulich S et al. Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy. J Am Coll Cardiol 2008;51:1022-30.
Syed IS, Glockner JF, Feng D, Araoz PA, Martinez MW, Edwards WD et al. Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC Cardiovasc Imaging 2010;3:155-64.
Fontana M, Banypersad SM, Treibel TA, Abdel-Gadir A, Maestrini V, Lane T et al. Differential myocyte responses in patients with cardiac transthyretin amyloidosis and light-chain amyloidosis: a cardiac MR imaging study. Radiology 2015;277:388-97.
Di Bella G, Pizzino F, Minutoli F, Zito C, Donato R, Dattilo G et al. The mosaic of the cardiac amyloidosis diagnosis: role of imaging in subtypes and stages of the disease. Eur Heart J Cardiovasc Imaging 2014;15:1307-15.
Bokhari S, Castano A, Pozniakoff T, Deslisle S, Latif F, Maurer MS. (99m)Tcpyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging 2013;6:195-201.
Hutt DF, Quigley AM, Page J, Hall ML, Burniston M, Gopaul D et al. Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis. Eur Heart J Cardiovasc Imaging 2014;15:1289-98.
Perugini E, Guidalotti PL, Salvi F, Cooke RM, Pettinato C, Riva L et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol 2005;46:1076-84.
Rapezzi C, Quarta CC, Guidalotti PL, Pettinato C, Fanti S, Leone O et al. Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretinrelated cardiac amyloidosis. JACC Cardiovasc Imaging 2011;4:659-70.
Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 2016;133:2404-12.
Cardim N, Galderisi M, Edvardsen T, Plein S, Popescu BA, D'Andrea A et al. Role of multimodality cardiac imaging in the management of patients with hypertrophic cardiomyopathy: an expert consensus of the European Association of Cardiovascular Imaging Endorsed by the Saudi Heart Association. Eur Heart J Cardiovasc Imaging 2015;16:280.
Bosi G, Crepaz R, Gamberini MR, Fortini M, Scarcia S, Bonsante E et al. Left ventricular remodelling, and systolic and diastolic function in young adults with beta thalassaemia major: a Doppler echocardiographic assessment and correlation with haematological data. Heart 2003;89:762-6.
Leon MB, Borer JS, Bacharach SL, Green MV, Benz EJ Jr, Griffith P et al. Detection of early cardiac dysfunction in patients with severe beta-thalassemia and chronic iron overload. N Engl J Med 1979;301:1143-8.
Kremastinos DT, Farmakis D, Aessopos A, Hahalis G, Hamodraka E, Tsiapras D et al. Beta-thalassemia cardiomyopathy: history, present considerations, and future perspectives. Circ Heart Fail 2010;3:451-8.
Cogliandro T, Derchi G, Mancuso L, Mayer MC, Pannone B, Pepe A et al. Society for the Study of Thalassemia and Hemoglobinopathies (SoSTE). Guideline recommendations for heart complications in thalassemia major. J Cardiovasc Med 2008;9:515-25.
Efthimiadis GK, Hassapopoulou HP, Tsikaderis DD, Karvounis HI, Giannakoulas GA, Parharidis GE et al. Survival in thalassaemia major patients. Circ J 2006;70:1037-42.
Giakoumis A, Berdoukas V, Gotsis E, Aessopos A. Comparison of echocardiographic (US) volumetry with cardiac magnetic resonance imaging in transfusion dependent thalassemia major. Cardiovasc Ultrasound 2007;5:24.
Pennell DJ, Udelson JE, Arai AE, Bozkurt B, Cohen AR, Galanello R et al. American Heart Association Committee on Heart Failure and Transplantation of the Council on Clinical Cardiology and Council on Cardiovascular Radiology and Imaging. Cardiovascular function and treatment in b-thalassemia major: a consensus statement from the American Heart Association. Circulation 2013;128:281-308.
Pepe A, Meloni A, Capra M, Cianciulli P, Prossomariti L, Malaventura C et al. Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging. Haematologica 2011;96:41-7.
Meloni A, Positano V, Ruffo GB, Spasiano A, D'Ascola D, Peluso A et al. Improvement of heart iron with preserved patterns of iron store by CMRguided chelation therapy. European Heart J Cardiovasc Imaging 2015;16:325-34.
Casale M, Meloni A, Filosa A, Cuccia L, Caruso V, Palazzi G et al. Multiparametric cardiac magnetic resonance survey in children with thalassemia major a multicenter study. Circ Cardiovasc Imaging 2015;8:e003230.
Pepe A, Positano V, Capra M, Maggio A, Pinto CL, Spasiano A et al. Myocardial scarring by delayed enhancement cardiovascular magnetic resonance in thalassaemia major. Heart 2009;95:1688-93.
Linhart A, Kampmann C, Zamorano JL, Sunder-Plassmann G, Beck M, Mehta A et al. European FOS Investigators. Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. Eur Heart J 2007;28:1228-35.
MacDermot KD, Holmes A, Miners AH. Natural history of Fabry disease in affected males and obligate carrier females. J Inherit Metab Dis 2001;24(Suppl 2):13-4.
Gambarin FI, Disabella E, Narula J, Diegoli M, Grasso M, Serio A et al. When should cardiologists suspect Anderson-Fabry disease? Am J Cardiol 2010;106:1492-9.
West M, Nicholls K, Mehta A, Clarke JT, Steiner R, Beck M et al. Agalsidase alpha and kidney dysfunction in Fabry disease. J Am Soc Nephrol 2009;20:1132-9.
Perrot A, Osterziel KJ, Beck M, Dietz R, Kampmann C. Fabry disease: focus on cardiac manifestations and molecular mechanisms. Herz 2002;27:699-702.
Nagueh SF. Anderson-Fabry disease and other lysosomal storage disorders. Circulation 2014;130:1081-90.
Weidemann F, Linhart A, Monserrat L, Strotmann J. Cardiac challenges in patients with Fabry disease. Int J Cardiol 2010;141:3-10.
Hoigné P, Attenhofer Jost CH, Duru F, Oechslin EN, Seifert B, Widmer U et al. Simple criteria for differentiation of Fabry disease from amyloid heart disease and other causes of left ventricular hypertrophy. Int J Cardiol 2006;111:413-22.
Feriozzi S, Schwarting A, Sunder-Plassmann G, West M, Cybulla M. International Fabry Outcome Survey Investigators. Agalsidase alpha slows the decline in renal function in patients with Fabry disease. Am J Nephrol 2009;29:353-61.
Pieroni M, Chimenti C, Russo A, Russo MA, Maseri A, Frustaci A. Tissue Doppler imaging in Fabry disease. Curr Opin Cardiol 2004;19:452-7.
Toro R, Perez-Isla L, Doxastaquis G, Barba MA, Gallego AR, Pintos G et al. Clinical usefulness of tissue Doppler imaging in predicting preclinical Fabry cardiomyopathy. Int J Cardiol 2009;132:38-44.
Zamorano J, Serra V, Pérez de Isla L, Feltes G, Calli A, Barbado FJ et al. Usefulness of tissue Doppler on early detection of cardiac disease in Fabry patients and potential role of enzyme replacement therapy (ERT) for avoiding progression of disease. Eur J Echocardiogr 2011;12:671-7.
De Cobelli F, Esposito A, Belloni E, Pieroni M, Perseghin G, Chimenti C et al. Delayed-enhanced cardiac MRI for differentiation of Fabry's disease from symmetric hypertrophic cardiomyopathy. AJR Am J Roentgenol 2009;192: W97-102.
Boucek D, Jirikowic J, Taylor M. Natural history of Danon disease. Genet Med 2011;13:563-8.
Maron BJ, Roberts WC, Arad M, Haas TS, Spirito P, Wright GB et al. Clinical outcome and phenotypic expression in LAMP2 cardiomyopathy. JAMA 2009;301:1253-9.
D'souza RS, Levandowski C, Slavov D, Graw SL, Allen LA, Adler E et al. Danon disease: clinical features, evaluation, and management. Circ Heart Fail 2014;7:843-9.
Gussenhoven WJ, Busch HF, Kleijer WJ, de Villeneuve VH. Echocardiographic features in the cardiac type of glycogen storage disease II. Eur Heart J 1983;4:41-3.
Rees A, Elbl F, Minhas K, Solinger R. Echocardiographic evidence of outflow tract obstruction in Pompe's disease (glycogen storage disease of the heart). Am J Cardiol 1976;37:1103-6.
Barker PC, Pasquali SK, Darty S, Ing RJ, Li JS, Kim RJ et al. Use of cardiac magnetic resonance imaging to evaluate cardiac structure, function and fibrosis in children with infantile Pompe disease on enzyme replacement therapy. Mol Genet Metab 2010;101:332-7.
Nucifora G, Miani D, Piccoli G, Proclemer A. Cardiac magnetic resonance imaging in Danon disease. Cardiology 2012;121:27-30.
Wei LG, Gao JQ, Liu XM, Huang JM, Li XZ. A study of glycogen storage disease with 99Tcm-MIBI gated myocardial perfusion imaging. Ir J Med Sci 2013;182:615-20.
Lo Iudice F, Barbato A, Muscariello R, Di Nardo C, de Stefano F, Sibilio M et al. Left ventricular diastolic dysfunction in type I Gaucher Disease: An Echo Doppler Study. Echocardiography 2015;32:890-5.
Braunlin E, Wang R. Cardiac issues in adults with mucopolysaccharidoses; current knowledge and emerging needs. Heart 2016;102:1257-62.
Przybojewski JZ, Maritz F, Tiedt FA, van der Walt JJ. Pseudoxanthoma elasticum with cardiac involvement. A case report and review of the literature. S Afr Med J 1981;59:268-75.
Campens L, Vanakker OM, Trachet B, Segers P, Leroy BP, De Zaeytijd J et al. Characterization of cardiovascular involvement in pseudoxanthoma elasticum families. Arterioscler Thromb Vasc Biol 2013;33:2646-52.
Nguyen LD, Terbah M, Daudon P, Martin L. Left ventricular systolic and diastolic function by echocardiogram in pseudoxanthoma elasticum. Am J Cardiol 2006;97:1535-7.
Sabán-Ruiz J, Fabregate Fuente R, Sánchez-Largo Uceda E, Fabregate Fuente M. Pseudoxanthoma elasticum: case report with arterial stiffness evaluated by a research cardiovascular profiling system. Eur J Dermatol 2010;20:785-7.
Kandolin R, Lehtonen J, Airaksinen J, Vihinen T, Miettinen H, Ylitalo K et al. Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study. Circulation 2015;131:624-32.
Birnie DH, Sauer WH, Bogun F, Cooper JM, Culver DA, Duvernoy CS et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm 2014;11:1305-23.
Judson MA, Costabel U, Drent M, Wells A, Maier L, Koth L et al. Organ Assessment Instrument Investigators TW. The WASOG Sarcoidosis Organ Assessment Instrument: An update of a previous clinical tool. Sarcoidosis Vasc Diffuse Lung Dis 2014;31:19-27.
Chiu CZ, Nakatani S, Yamagishi M, Miyatake K, Cheng JJ. Echocardiographic Manifestations in Patients with Cardiac Sarcoidosis. J Med Ultrasound 2002;10:135-40.
Hourigan LA, Burstow DJ, Pohlner P, Clarke BE, Donnelly JE. Transesophageal echocardiographic abnormalities in a case of cardiac sarcoidosis. J Am Soc Echocardiogr 2001;14:399-402.
Patel MR, Cawley PJ, Heitner JF, Klem I, Parker MA, Jaroudi WA. Detection of myocardial damage in patients with sarcoidosis. Circulation 2009;120:1969-77.
Hundley WG, Bluemke DA, Finn JP, Flamm SD, Fogel MA, Friedrich MG et al. ACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. J Am Coll Cardiol 2010;55:2614-62.
Schulz-Menger J, Wassmuth R, Abdel-Aty H, Siegel I, Franke A, Dietz R, Friedrich M G. Patterns of myocardial inflammation and scarring in sarcoidosis as assessed by cardiovascular magnetic resonance. Heart 2006;92:399-400.
Seward JB, Casaclang-Verzosa G. Infiltrative cardiovascular diseases: cardiomyopathies that look alike. J Am Coll Cardiol 2010;55:1769-79.
Lancefield T, Voskoboinik A, Taylor AJ, Nadel J. Late gadolinium enhancement identified with cardiac magnetic resonance imaging in sarcoidosis patients is associated with long-term ventricular arrhythmia and sudden cardiac death. Eur Heart J Cardiovasc Imaging 2015;16:634-41.
Okumura W, Iwasaki T, Toyama T, Iso T, Arai M, Oriuchi N et al. Usefulness of fasting 18F-FDG PET in identification of cardiac sarcoidosis. J Nucl Med 2004;45:1989-98.
Keijsers RG, Grutters JC, Thomeer M, Du Bois RM, Van Buul MM, Lavalaye FJ. et al. Imaging the inflammatory activity of sarcoidosis: sensitivity and inter observer agreement of (67)Ga imaging and (18)F-FDG PET. Q J Nucl Med Mol Imaging 2011;55:66-71
Ishimaru S, Tsujino I, Takei T, Tsukamoto E, Sakaue S, Kamigaki M et al. Focal uptake on 18F-fluoro-2-deoxyglucose positron emission tomography images indicates cardiac involvement of sarcoidosis. Eur Heart J 2005;26:1538-43.
Youssef G, Leung E, Mylonas I, Nery P, Williams K, Wisenberg G et al. The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and metaanalysis including the Ontario experience. J Nucl Med 2012;53:241-8.
Tang R, Wang JT, Wang L, Le K, Huang Y, Hickey AJ et al. Impact of patient preparation on the diagnostic performance of 18F-FDG PET in cardiac sarcoidosis: a systematic review and meta-analysis. Clin Nucl Med 2016;41:e327-39.
Skali H, Schulman AR, Dorbala S. (18)F-FDG PET/CT for the assessment of myocardial sarcoidosis. Curr Cardiol Rep 2013;15:352.
Blankstein R, Osborne M, Naya M, Waller A, Kim CK, Murthy VL et al. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoid. J Am Coll Cardiol 2014;63:329-36
Yokoyama R, Miyagawa M, Okayama H, Inoue T, Miki H, Ogimoto A et al. Quantitative analysis of myocardial 18F-fluorodeoxyglucose uptake by PET/CT for detection of cardiac sarcoidosis. Int J Cardiol 2015;195:180-7
Yamagishi H, Shirai N, Takagi M, Yoshiyama M, Akioka K, Takeuchi K et al. Identification of cardiac sarcoidosis with (13) N-NH(3)/[18F]FDG PET. J Nucl Med 2003;44:1030-6.
Osborne MT1, Hulten EA, Singh A, Waller AH, Bittencourt MS, Stewart GC et al. Reduction in 18F-fluorodeoxyglucose uptake on serial cardiac positron emission tomography is associated with improved left ventricular ejection fraction in patients with cardiac sarcoidosis. J Nucl Cardiol 2014;21:166-74.
Ohira H, Birnie DH, Pena E, Bernick J, Mc Ardle B, Leung E et al. Comparison of (18)F-fluorodeoxyglucose positron emission tomography (FDG PET) and cardiac magnetic resonance (CMR) in corticosteroid-naive patients with conduction system disease due to cardiac sarcoidosis. Eur J Nucl Med Mol Imaging 2016;43:259-69.
Leask A. The role of endothelin-1 signaling in the fibrosis observed in systemic sclerosis. Pharmacol Res 2011;63:502-3.
Tyndall AJ, Bannert B, Vonk M, Airo P, Cozzi F, Carreira PE et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010;69:1809-15.
Follansbee WP, Miller TR, Cirtoss EI, Orie JE, Bernstein RL, Kiernan JM et al. A controlled clinicopathologic study of myocardial fibrosis in systemic sclerosis (scleroderma). J Rheumatol 1990;17:656-62.
Meune C, Avouac J, Wahbi K, Cabanes L, Wipff J, Mouthon L et al. Cardiac involvement in systemic sclerosis assessed by tissue-doppler echocardiography during routine care: a controlled study of 100 consecutive patients. Arthritis Rheum 2008;58:1803-9.
Allanore Y, Meune C, Vonk MC, Airo P, Hachulla E, Caramaschi P et al. Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis. Ann Rheum Dis 2010;69:218-21.
D'Andrea A, Stisi S, Bellissimo S, Vigorito F, Scotto di Uccio F, Tozzi N et al. Early impairment of myocardial function in systemic sclerosis: non-invasive assessment by Doppler myocardial and strain rate imaging. Eur J Echocardiogr 2005;6:407-18.
Yiu KH, Schouffoer AA, Marsan NA, Ninaber MK, Stolk J, Vlieland TV et al. Left ventricular dysfunction assessed by speckle-tracking strain analysis in patients with systemic sclerosis. Arthritis Rheum 2011;63:3969-78.
Mueller KA, Mueller II, Eppler D, Zuern CS, Seizer P, Kramer U et al. Clinical and histopathological features of patients with systemic sclerosis undergoing endomyocardial biopsy. PLoS One 2015;10:e0126707.
Hachulla AL, Launay D, Gaxotte V, deGroote P, Lamblin N, Devos P et al. Cardiac magnetic resonance imaging in systemic sclerosis: a cross-sectional observational study of 52 patients. Ann Rheum Dis 2009;68:1878-84.
Ugander M, Oki AJ, Hsu LY, Kellman P, Greiser A, Aletras AH et al. Extracellular volume imaging by magnetic resonance imaging provides insights into overt and sub-clinical myocardial pathology. Eur Heart J 2012;33:1268-78.
Barison A, Gargani L, De Marchi D, Aquaro GD, Guiducci S, Picano E et al. Early myocardial and skeletal muscle interstitial remodelling in systemic sclerosis: insights from extracellular volume quantification using cardiovascular magnetic resonance. Eur Heart J Cardiovasc Imaging 2015;16:74-80.
Thuny F, Lovric D, Schnell F, Bergerot C, Ernande L, Cottin V et al. Quantification of myocardial extracellular volume fraction with cardiac MR imaging for early detection of left ventricle involvement in systemic sclerosis. Radiology 2014;271:373-80.
Follansbee WP, Curtiss EI, Medsger TA Jr, Steen VD, Uretsky BF, Owens GR et al. Physiologic abnormalities of cardiac function in progressive systemic sclerosis with diffuse scleroderma. N Engl J Med 1984;310:142-8.
Lancellotti P, Nkomo VT, Badano LP, Bergler-Klein J, Bogaert J, Davin L et al. Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. Eur Heart J Cardiovasc Imaging 2013;14:721-40.
Messroghli D, Nordmeyer S, Dietrich T, Dirsch O, Kaschina E, Savvatis K et al. Assessment of diffuse myocardial fibrosis in rats using small-animal Look-Locker inversion recovery T1 mapping. Circ Cardiovasc Imaging 2011;4:636-40.
Constine L, Schwartz R, Savage D, King V, Muhs A. Cardiac function, perfusion, and morbidity in irradiated long-term survivors of Hodgkin's disease. Int J Radiat Oncol Biol Phys 1997;39:897-906.
Marks L, Yu X, Prosnitz R, Zhou SM, Hardenbergh P, Blazing M et al. The incidence and functional consequences of RT-associated cardiac perfusion defects. Int J Radiat Oncol Biol Phys 2005;63:214-23.
Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2014;15:1063-93.
Dato I. How to recognize endomyocardial fibrosis? J Cardiovasc Med 2015;16:547-51.
Mocumbi AO. Endomyocardial fibrosis: A form of endemic restrictive cardiomyopathy. Glob Cardiol Sci Pract 2012;2012:11.
Bukhman G, Ziegler J, Parry E. Endomyocardial fibrosis: still a mystery after 60 years. PLoS Negl Trop Dis 2008;2:e97.
Mocumbi AO, Carrilho C, Sarathchandra P, Ferreira MB, Yacoub M, Burke M. Echocardiography accurately assesses the pathological abnormalities of chronic endomyocardial fibrosis. Int J Cardiovasc Imaging 2011;27:955-64.
Mocumbi AO, Ferreira MB, Sidi D, Yacoub MH. A population study of endomyocardial fibrosis in a rural area of Mozambique. N Engl J Med 2008;359:43-9.
Kharabish A, Haroun D. Cardiac MRI findings of endomyocardial fibrosis (Loeffler's endocarditis) in a patient with rheumatoid arthritis. J Saudi Heart Assoc 2015;27:127-31.
Schneeweis C, Berger A, Kelle S, Fleck E, Gebker R. Endomyocardial fibrosis in patients with confirmed Churg-Strauss syndrome. Rheumatology 2014;53: 84.
Maia CP, Gali LG, Schmidt A, de Almeida Filho OC, Santos MK et al. A challenging differential diagnosis: distinguishing between endomyocardial fibrosis and apical hypertrophic cardiomyopathy. Echocardiography 2016;33:1080-4.
Cury R, Abbara S, Sandoval LJ, Houser S, Brady T and Palacios IF. Visualization of endomyocardial fibrosis by delayed-enhancement magnetic resonance. Imaging Circulation 2005;111:e115-7.
Salemi VMC, Rochitte CE, Shiozaki AA, Andrade JM, Parga JR, de Ávila LF et al. Late gadolinium enhancement magnetic resonance imaging in the diagnosis and prognosis of endomyocardial fibrosis patients. Circ Cardiovasc Imaging 2011;4:304-11.
Al Ali AM, Straatman LP, Allard MF, Ignaszewski AP. Eosinophilic myocarditis: case series and review of literature. Can J Cardiol 2006;22:1233-7.
Ommen SR, Seward JB, Tajik AJ. Clinical and echocardiographic features of hypereosinophilic syndromes. Am J Cardiol 2000;1:110-3.
Simonnet B, Jacquier A, Salaun E, Hubert S, Habib G. Cardiac involvement in hypereosinophilic syndrome: role of multimodality imaging. Eur Heart J Cardiovasc Imaging 2015;16:228.
Acquatella H, Schiller NB, Puigbó JJ, Gómez-Mancebo JR, Suarez C, Acquatella G. Value of two-dimensional echocardiography in endomyocardial disease with and without eosinophilia. A clinical and pathologic study. Circulation 1983;67:1219-26.
Rotoli B, Catalano L, Galderisi M, Luciano L, Pollio G, Guerriero A et al. Rapid reversion of Loeffler's endocarditis by imatinib in early stage clonal hypereosinophilic syndrome. Leuk Lymphoma 2004;45:2503-7.
Puvaneswary M, Joshua F, Ratnarajah S. Idiopathic hypereosinophilic syndrome: magnetic resonance imaging findings in endomyocardial fibrosis. Australas Radiol 2001;45:524-7.
Porto AG, McAlindon E, Hamilton M, Manghat N, Bucciarelli-Ducci C. Diagnosing cardiac involvement in the hypereosinophilic syndrome by cardiac magnetic resonance. Am J Cardiol 2013;112:135-6.
Pillar N, Halkin A, Aviram G. Hypereosinophilic syndrome with cardiac involvement: early diagnosis by cardiac magnetic resonance imaging. Can J Cardiol 2012;515:e11-3.
ten Oever J, Theunissen LJ, Tick LW, Verbunt RJ. Cardiac involvement in hypereosinophilic syndrome. Neth J Med 2011;69:240.
Haugaa KH, Bergestuen DS, Sahakyan LG, Skulstad H, Aakhus S, Thiis-Evensen E et al. Evaluation of right ventricular dysfunction by myocardial strain echocardiography in patients with intestinal carcinoid disease. J Am Soc Echocardiogr 2011;24:644-50.
Modlin IM, Shapiro MD, Kidd M. Carcinoid tumors and fibrosis: an association with no explanation. Am J Gastroenterol 2004;99:2466-78.
Pellikka PA, Tajik AJ, Khandheria BK, Seward JB, Callahan JA, Pitot HC et al. Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients. Circulation 1993;87:1188-96.
Urheim S, Edvardsen T, Torp H, Angelsen B, Smiseth OA. Myocardial strain by Doppler echocardiography. Validation of a new method to quantify regional myocardial function. Circulation 2000;102:1158-64.
Zahid W, Bergestuen D, Haugaa KH, Ueland T, Thiis-Evensen E, Aukrust P et al. Myocardial function by two-dimensional speckle tracking echocardiography and activin A may predict mortality in patients with carcinoid intestinal disease. Cardiology 2015;132:81-90.
Moerman VM, Dewilde D, Hermans K. Carcinoid heart disease: typical findings on echocardiography and cardiac magnetic resonance. Acta Cardiol 2012;67:245-8.
Nebigil CG, Etienne N, Messaddeq N, Maroteaux L. Serotonin is a novel survival factor of cardiomyocytes: mitochondria as a target of 5-ht2b receptor signaling. FASEB J 2003;17:1373-5.
Hutcheson JD, Setola V, Roth BL, Merryman WD. Serotonin receptors and heart valve disease-it was meant 2b. Pharmacol Ther 2011;132:146-57.
Fielden MR, Hassani M, Uppal H, Day-Lollini P, Button D, Martin RS et al. Mechanism of subendocardial cell proliferation in the rat and relevance for understanding drug-induced valvular heart disease in humans. Exp Toxicol Pathol 2010;62:607-13.
Fowles RE, Cloward TV, Yowell RL. Endocardial fibrosis associated with fenfluramine-phentermine. N Engl J Med 1998;338:1316.
Szymanski C, Marechaux S, Bruneval P, Andrejak M, de Montpréville VT, Belli E et al. Sub obstruction of left outflow tract secondary to benfluorex-induced endocardial fibrosis. IJC Heart Vasculature 2015;9:67-9
Vaitkus PT, Kussmaul WG. Constrictive pericarditis versus restrictive cardiomyopathy: a reappraisal and update of diagnostic criteria. Am Heart J 1991;122:1431-41.
Shabetai R. Pathophysiology and differential diagnosis of restrictive cardiomyopathy. Cardiovasc Clin 1988;19:123-32.
Kusunose K, Dahiya A, Popović ZB, Motoki H, Alraies MC, Zurick AO et al. Biventricular mechanics in constrictive pericarditis comparison with restrictive cardiomyopathy and impact of pericardiectomy. Circ Cardiovasc Imaging 2013;6:399-406.
Welch TD, Ling LH, Espinosa RE, Anavekar NS, Wiste HJ, Lahr BD et al. Echocardiographic diagnosis of constrictive pericarditis. Mayo clinic criteria. Circ Cardiovasc Imaging 2014;7:526-34.
Ha JW, Ommen SR, Tajik AJ, Barnes ME, Ammash NM, Gertz MA et al. Differentiation of constrictive pericarditis from restrictive cardiomyopathy using mitral annular velocity by tissue Doppler echocardiography. Am J Cardiol 2004;94:316-9.
Ha JW, Oh JK, Ommen SR, Ling LH, Tajik AJ. Diagnostic value of mitral annular velocity for constrictive pericarditis in the absence of respiratory variation in mitral inflow velocity. J Am Soc Echocardiogr 2002;15:1468-71.
Sengupta PP, Mohan JC, Mehta V, Arora R, Pandian NG, Khandheria BK. Accuracy and pitfalls of early diastolic motion of the mitral annulus for diagnosing constrictive pericarditis by tissue Doppler imaging. Am J Cardiol 2004;93:886-90.
Rajagopalan N, Garcia MJ, Rodriguez L, Murray RD, Apperson-Hansen C, Stugaard M et al. Comparison of new Doppler echocardiographic methods to differentiate constrictive pericardial heart disease and restrictive cardiomyopathy. Am J Cardiol 2001;87:86-94.
Amaki M, Savino J, Ain DL, Sanz J, Pedrizzetti G, Kulkarni H et al. Diagnostic concordance of echocardiography and cardiac magnetic resonance-based tissue tracking for differentiating constrictive pericarditis from restrictive cardiomyopathy. Circ Cardiovasc Imaging 2014;7:819-27.
Adler Y, Charron P, Imazio M, Badano L, Baron-Esquivias G, Bogaert J et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2015;36:2921-64.
Talreja DR, Edwards WD, Danielson GK, Schaff HV, Tajik AJ, Tazelaar HD et al. Constrictive pericarditis in 26 patients with histologically normal pericardial thickness. Circulation 2003;108:1852-7.
Yared K, Baggish AL, Picard MH, Hoffmann U, Hung J. Multimodality imaging of pericardial diseases. JACC Cardiovasc Imaging 2010;3:650-60.
Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology. Eur Heart J 2014;35:2733-92.
Olivotto I, Maron BJ, Appelbaum E, Harrigan CJ, Salton C, Gibson CM et al. Spectrum and clinical significance of systolic function and myocardial fibrosis assessed by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. Am J Cardiol 2010;106:261-7.
Biagini E, Spirito P, Rocchi G, Ferlito M, Rosmini S, Lai F et al. Prognostic implications of the Doppler restrictive filling pattern in hypertrophic cardiomyopathy. Am J Cardiol; 104:1727-31.
Melacini P, Basso C, Angelini A, Calore C, Bobbo F, Tokajuk B et al. Clinicopathological profiles of progressive heart failure in hypertrophic cardiomyopathy. Eur Heart J 2010;31:2111-23.
Nistri S, Olivotto I, Betocchi S, Losi MA, Valsecchi G, Pinamonti B et al. Prognostic significance of left atrial size in patients with hypertrophic cardiomyopathy (from the Italian Registry for Hypertrophic Cardiomyopathy). Am J Cardiol 2006;98:960-5.
Maron BJ, Spirito P. Implications of left ventricular remodeling in hypertrophic cardiomyopathy. Am J Cardiol 1998;81:1339-448.
Olivotto I, Cecchi F, Poggesi C, Yacoub MH. Patterns of disease progression in hypertrophic cardiomyopathy: an individualized approach to clinical staging. Circ Heart Fail 2012;5:535-46.
Habib G, Charron P, Eicher JC, Giorgi R, Donal E, Laperche T et al. Working Groups 'Heart Failure and Cardiomyopathies' and 'Echocardiography' of the French Society of Cardiology. Isolated left ventricular non-compaction in adults: clinical and echocardiographic features in 105 patients. Results from a French registry. Eur J Heart Fail 2011;13:177-85.
Rapezzi C, Leone O, Ferlito M, Biagini E, Coccolo F, Arpesella G. Isolated ventricular non-compaction with restrictive cardiomyopathy. Eur Heart J 2006;27:1927.
